Last updated: July 17, 2026

Application No. 18/572,451

MATERIALS AND METHODS FOR ENHANCED DETECTION AND SCREENING OF MOLECULES OF THERAPEUTIC POTENTIAL

Non-Final OA

Filed

Dec 20, 2023

Priority

Jun 23, 2021 — provisional 63/214,177 +2 more

Examiner

OGUNTADE, ELIZABETH BISOLA

Art Unit

Tech Center

Assignee

Janssen Pharmaceuticals Inc.

OA Round

1 (Non-Final)

Interview Optional

— +0.0% interview lift. Interview lift (+0.0%) is below the 15.0% threshold. A written response is recommended.

Based on 1 resolved cases, 2023–2026

Examiner Intelligence

OGUNTADE, ELIZABETH BISOLA View full profile →

Grants only 0% of cases

Career Allowance Rate

0 granted / 1 resolved

-60.0% vs TC avg

Minimal +0% lift

Without

With

+0.0%

Interview Lift

resolved cases with interview

Fast prosecutor

1y 8m

Avg Prosecution

27 currently pending

Career history

Total Applications

across all art units

Statute-Specific Performance

§101

8.8%

-31.2% vs TC avg

§103

63.2%

+23.2% vs TC avg

§102

3.5%

-36.5% vs TC avg

§112

7.0%

-33.0% vs TC avg

Black line = Tech Center average estimate • Based on career data from 1 resolved cases

Prosecution Timeline

Dec 20, 2023

Application Filed

Jun 05, 2026

Non-Final Rejection mailed (current)

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2

Expected OA Rounds

Grant Probability

With Interview (+0.0%)

1y 8m (~0m remaining)

Median Time to Grant

Low

PTA Risk

Based on 1 resolved cases by this examiner. Grant probability derived from career allowance rate.